As of April 1, 2024, patients with multiple sclerosis will have access to a new subcutaneous form of natalizumab therapy administration. According to Prof. Monika Adamczyk-Sowa, MD, head of the Department of Neurology in Zabrze at the Silesian Medical University in Katowice, and president of the MS and Neuroimmunology Section of the PTN: "The possibility of subcutaneous therapy is a significant convenience for patients, as it allows for a significant reduction in the time of administration of the drug, and thus the stay in the institution. This improves the overall comfort and quality of life of patients on chronic therapy."
Today, multiple sclerosis is a very different disease, with a different course and a different prognosis than just a dozen years ago. Thanks to highly effective immunomodulatory drugs, the progression of this disease can be completely halted in most people.
According to the Ministry of Health, natalizumab treatment in subcutaneous form will be available to all patients after intolerance to therapy with natalizumab i.v. (in the intravenous form) due to phlebitis after int...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
